Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
Authors:
- Rene ClaveroRCRene Clavero
- Alfredo Parra-LucaresAPAlfredo Parra-Lucares
- Gabriel Méndez-ValdésGMGabriel Méndez-Valdés
- Eduardo VillaEduardo Villa
- Karin BravoKBKarin Bravo
- Evelyn MondacaEMEvelyn Mondaca
- Josseline ArandaJAJosseline Aranda
- Rose BrignardelloRBRose Brignardello
- Cynthia GajardoCGCynthia Gajardo
- Angelica OrdenesAOAngelica Ordenes
- Evelyn ColomboECEvelyn Colombo
- Jessica TapiaJTJessica Tapia
Open Access
Abstract
The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2. End-stage renal disease (ESRD) patients have an increased rate of COVID-19 and a reduced immune response to vaccinations. Currently, there is little data on this population’s immune response induced by CoronaVac. Methods: This study involved a prospective cohort of ESRD patients in chronic hemodialysis who received a two-dose immunization scheme of either CoronaVac (Sinovac Biotech) or BNT162b2 vaccines (Pfizer-BioNTech). We measured the plasma levels of anti-SARS-CoV-2 IgG antibodies. We determined antibody titers before immunization, 2 and 4 months after two doses, plus 4 months after a booster dose. Results: We evaluated 208 patients in three hemodialysis centers. The mean age was 62.6 ± 15.6 years, of whom 91 were female (41.75%). Eighty-one patients (38.94%) received the BNT162b2 vaccine and 127 (61.06%) received the CoronaVac vaccine. Patients who received the BNT162b2 vaccine had a higher humoral response compared to those who received the CoronaVac vaccine (4 months after the second dose: BNT162b2: 88.89%, CoronaVac: 51.97%, p < 0.001; 4 months after the booster: BNT162b2: 98.77%, CoronaVac: 86.61%, p < 0.001). Conclusions: Our results suggest that the CoronaVac vaccine induced a lower humoral response than the BNT162b2 vaccine in ESRD patients on hemodialysis.Keywords
Funding Information
- Fondecyt Regular (1221571)
This publication has 29 references indexed in Scilit:
- Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2021
- Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance HemodialysisClinical Journal of the American Society of Nephrology, 2021
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2Nature, 2021
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19New England Journal of Medicine, 2021
- Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controlsNephrology Dialysis Transplantation, 2021
- Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyNature Medicine, 2021
- Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT studyClinical Kidney Journal, 2021
- Outcomes of patients with end-stage kidney disease hospitalized with COVID-19Kidney International, 2020
- Covid-19 en pacientes renales crónicos: llamado de atenciónRevista médica de Chile, 2020
- COVID-19: what has been learned and to be learned about the novel coronavirus diseaseInternational Journal of Biological Sciences, 2020